- Home
- ORKA vs WFG Comparison
ORKA vs WFG Comparison
Compare ORKA & WFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ORKA | WFG |
|---|---|---|
| Founded | 2004 | 1955 |
| Country | United States | Canada |
| Employees | 68 | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.0B |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | ORKA | WFG |
|---|---|---|
| Price | $87.48 | $71.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 2 |
| Target Price | ★ $92.50 | $89.50 |
| AVG Volume (30 Days) | ★ 1.6M | 155.8K |
| Earning Date | 05-13-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 2.03% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $5.05 |
| Revenue Next Year | N/A | $10.26 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.84 | $57.34 |
| 52 Week High | $97.78 | $76.99 |
Technical Indicators
Market Signals| Indicator | ORKA | WFG |
|---|---|---|
| Relative Strength Index (RSI) | 58.78 | 61.36 |
| Support Level | $81.15 | $58.54 |
| Resistance Level | $91.00 | $76.77 |
| Average True Range (ATR) | 5.23 | 1.95 |
| MACD | -0.85 | 0.17 |
| Stochastic Oscillator | 32.08 | 90.19 |
Price Performance
Historical ComparisonAbout ORKA Oruka Therapeutics Inc.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
About WFG West Fraser Timber Co. Ltd.
West Fraser Timber is a softwood lumber company that also produces wood panels and pulp products. The company produces its wood products globally, with lumber mills in British Columbia, Alberta, Europe, and the Southeastern United States. Following its acquisition of Norbord in 2021, West Fraser is one of the largest oriented strand board producers in the world.